Chimerix Investor Conference Presentation Deck

● ● Dosing & Disposition Dosing Oral 625 mg ONC201 (scaled by body weight for pediatric patients) Once every week with exception of one patient dosed once every 3 weeks Last patient enrolled February 26, 2020 Data cutoff for analysis May 31, 2021 Median follow-up 18.8 months - - Disposition Five patients remain on study drug; four patients continue post-progression - 11

View entire presentation